Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

ASC30

Stage Phase 3Stale

Sponsor Ascletis Pharma (China) Co

Route oral and injection

Sources

registry, as of 2026-09-16Stale

https://clinicaltrials.gov/study/NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities. Overall status RECRUITING. Phases PHASE3. Lead sponsor Ascletis Pharma (China) Co., Limited. Enrollment 3003. Conditions Obesity; Overweight; Chronic Weight Management. Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesit

ClinicalTrials.gov NCT07743463 protocol and results modules

registry, as of 2026-09-16Stale

https://clinicaltrials.gov/study/NCT07743450

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes. Overall status RECRUITING. Phases PHASE3. Lead sponsor Ascletis Pharma (China) Co., Limited. Enrollment 1560. Conditions Obesity; Overweight; Chronic Weight Management; Type 2 Diabetes Mellitus. Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesit

ClinicalTrials.gov NCT07743450 protocol and results modules

registry, as of 2025-12-15Stale

https://clinicaltrials.gov/study/NCT07002905

A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities. Overall status COMPLETED. Phases PHASE2. Lead sponsor Ascletis Pharma (China) Co., Limited. Enrollment 125. Conditions Chronic Weight Management. This randomized, double-blind, placebo-controlled phase IIa study is designed to evaluate the efficacy, safety, and tolerability of ASC30 Tablets and ASC30 Tablets A1.

ClinicalTrials.gov NCT07002905 protocol and results modules

registry, as of 2026-06-26Stale

https://clinicaltrials.gov/study/NCT06679959

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor Ascletis Pharma (China) Co., Limited. Enrollment 115. Conditions Chronic Weight Management. This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASC30 injection

ClinicalTrials.gov NCT06679959 protocol and results modules

registry, as of 2025-05-20Stale

https://clinicaltrials.gov/study/NCT06680440

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Ascletis Pharma (China) Co., Limited. Enrollment 72. Conditions Weight Management. This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, efficacy, food effect of ASC30 Tablets or ASC30 Tablets A1 in participants with obesity.

ClinicalTrials.gov NCT06680440 protocol and results modules

Studies

AURORA-1

Registry NCT07743463

Phase Phase 3

Status Recruiting

Enrollment 3003

Start 2026-08-31

ASC30 Cohort 1

Regimen once daily

Comparator placebo

Population Obesity; Overweight; Chronic Weight Management

ASC30 Cohort 2

Regimen once daily

Comparator placebo

Population Obesity; Overweight; Chronic Weight Management

ASC30 Cohort 3

Regimen once daily

Comparator placebo

Population Obesity; Overweight; Chronic Weight Management

Placebo Cohort 4

Regimen once daily

Population Obesity; Overweight; Chronic Weight Management

AURORA-2

Registry NCT07743450

Phase Phase 3

Status Recruiting

Enrollment 1560

Start 2026-08-28

ASC30 Cohort 1

Regimen once daily

Comparator placebo

Population Obesity; Overweight; Chronic Weight Management; Type 2 Diabetes Mellitus

ASC30 Cohort 2

Regimen once daily

Comparator placebo

Population Obesity; Overweight; Chronic Weight Management; Type 2 Diabetes Mellitus

ASC30 Cohort 3

Regimen once daily

Comparator placebo

Population Obesity; Overweight; Chronic Weight Management; Type 2 Diabetes Mellitus

Placebo Cohort 4

Regimen once daily

Population Obesity; Overweight; Chronic Weight Management; Type 2 Diabetes Mellitus

A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities

Registry NCT07002905

Phase Phase 2

Status Completed

Enrollment 125

Start 2025-07-03

Primary completion 2025-12-08

Study completion 2025-12-08

Catalyst Primary completion. 2025-12-08. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cohort 1

Regimen once daily

Population Chronic Weight Management

Cohort 2

Regimen once daily

Population Chronic Weight Management

Cohort 3

Regimen once daily

Population Chronic Weight Management

Cohort 4

Regimen once daily

Population Chronic Weight Management

Cohort 5

Regimen once daily

Population Chronic Weight Management

Cohort 6

Regimen once daily

Population Chronic Weight Management

Cohort 7

Regimen once daily

Population Chronic Weight Management

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity

Registry NCT06679959

Phase Phase 1/2

Status Completed

Enrollment 115

Start 2024-09-16

Primary completion 2026-03-26

Study completion 2026-03-26

Catalyst Primary completion. 2026-03-26. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

SAD Cohort 1

Population Chronic Weight Management

SAD Cohort 2

Population Chronic Weight Management

SAD Cohort 3

Population Chronic Weight Management

SAD Cohort 4

Population Chronic Weight Management

SAD Cohort 5

Population Chronic Weight Management

SAD Cohort 6

Population Chronic Weight Management

SAD Cohort 7

Population Chronic Weight Management

SAD Cohort 8

Population Chronic Weight Management

MAD Cohort 1

Population Chronic Weight Management

MAD Cohort 2

Population Chronic Weight Management

MAD Cohort 3

Population Chronic Weight Management

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity

Registry NCT06680440

Phase Phase 1

Status Completed

Enrollment 72

Start 2024-08-26

Primary completion 2025-04-03

Study completion 2025-04-03

Catalyst Primary completion. 2025-04-03. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

SAD Cohort 1

Population Weight Management

SAD Cohort 2

Population Weight Management

SAD Cohort 3

Population Weight Management

SAD Cohort 4

Population Weight Management

SAD Cohort 5

Population Weight Management

MAD Cohort 1

Population Weight Management

MAD Cohort 2

Population Weight Management

MAD Cohort 3

Population Weight Management